Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
Repligen (NASDAQ:RGEN) will present at the J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Repligen (NASDAQ:RGEN) will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco, January 12–15, 2026.
Olivier Loeillot, President and CEO, will deliver an overview of the company on Tuesday, January 13 at 2:15 p.m. PT. A live webcast will be available on Repligen’s investor relations website and will be replayable for a limited period after the event.
Details
News Market Reaction – RGEN
On Dec 18, the day this news came out, RGEN closed 0.51% above the previous close.
Data tracked by StockTitan Argus for the Dec 18 session.
Key Figures
- Conference dates
- January 12–15, 2026
- J.P. Morgan 2026 Healthcare Conference schedule
- Company presentation time
- 2:15 p.m. PT
- Repligen overview on Tuesday, January 13
- Previous close price
- $156.92
- Price before J.P. Morgan conference news
- 24h price change
- -0.74%
- Pre-news daily move
- 52-week range
- $102.97 – $182.52
- Low to high prior to this announcement
- Market cap
- $8,899,004,509
- Equity value prior to conference announcement
- 200-day MA
- $134.75
- Long-term trend reference level
- CEO sale
- 7,041 shares at $170
- Form 4 filed 2025-11-26 under Rule 10b5-1 plan
Historical Context
-
Launch of three new high-performance chromatography resins for gene therapy workflows.
-
Planned participation in Evercore Healthcare Conference with webcast access.
-
Attendance at five November investor conferences with executive presentations.
-
Q3 2025 beat with guidance raised and broad-based double-digit growth reported.
-
Announcement of Q3 2025 reporting date and related conference call details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Jargon Translator
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan 2026 Healthcare Conference, being held January 12 – 15 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 13 at 2:15 p.m. PT.
A live webcast of the conference presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.